Navigation Links
ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
Date:12/4/2008

/www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncert
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
2. Loic Maurel Joins Exonhit Therapeutics to Become CEO
3. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
4. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
5. ExonHit Appoints a New Management Board
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Builds A New Organisation
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014  An entire month ... of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – a ... legs, causing extreme muscle atrophy, weakness, and foot and ... US and millions worldwide. CMT is a progressive disease, ... their legs, requiring mobility devices such as leg braces, ...
(Date:9/19/2014)... 19, 2014 Biotech companies make ... emerging drug systems and advanced Laboratory Instrumentation. Companies in ... (NYSE: BDX ), Thermo Fisher Scientific Inc. ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... ASHKELON, Israel, Sept. 14 Seambiotic, a global leader ... nutraceuticals and biofuel industries, has announced that Daniel Chinn has ... Daniel replaces founder and previous CEO Amnon Bechar who has ... , , Daniel joins Seambiotic following a ...
... BOZEN, Italy, September 14 Health Robotics today reported,that ... to,be deployed across all of its I.V. Compounding Centers in ... "After multi-year due diligence on 2 companies in the field ... technology [due to RIVA,s,publicly announced multi-year delays in bringing their ...
... , , , ... Incorporated (Nasdaq: GPRO ) announced today that it is spinning ... developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food ... will own 19.9% of the new company, Roka Bioscience, Inc. Affiliates ...
Cached Biology Technology:Seambiotic Appoints New CEO 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 2Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 3Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 4
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/18/2014)... can swim up to 400 kilometres in search of a ... change. , Clownfish spend their entire adult lives under the ... wander the open ocean, says study co-author, Dr Hugo Harrison ... (Coral CoE) at James Cook University. , "In the past ... given a rare glimpse into how far they can swim, ...
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Illinois, established at the University of Illinois last year ... Agriculture, will receive another $500,000 in grants over several ... fostering collaborations and the free flow of information among ... environment and agriculture. The center has three areas ...
... A new book, Speaking of Genetics: A ... in the field of genetics. The collection makes a compelling ... range of genetic questions as recounted by the scientists themselves. ... interfaces with genetics. All interviews were conducted by Jane ...
... New research from the Centre for Addiction and Mental Health ... Toronto, Canada provides further clues as to why Autism Spectrum ... scientists discovered that males who carry specific alterations of DNA ... of developing ASD. The research is published in the September ...
Cached Biology News:Center integrates human, animal, environmental health 2Center integrates human, animal, environmental health 3Link to autism in boys found in missing DNA 2
Mouse Anti-Human Kallikrein 2 (Hk2)...
... Polyclonal Antibody to Asb-2 (Ankyrin repeat and ... raised against synthetic peptides containing amino acids ... Human spleen lysate (Imgenex Catalog No. 40149) ... It should cross react with mouse and ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
... Neuronal (GLYT2). The antiserum has been tested ... system. The staining pattern obtained with AB1773 ... situ hybridization with probes to GLYT2 mRNA ... glycinergic neurons. Preabsorption of the antiserum with ...
Biology Products: